Navigation Links
Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
Date:2/7/2008

Aprotinin plus ACE inhibitor associated with renal woes during off-pump surgery, U.K. study finds

THURSDAY, Feb. 7 (HealthDay News) -- While use of the clotting drug aprotinin (Trasylol) appears safe during on-pump cardiac surgeries, combining it with angiotensin-converting enzyme (ACE) inhibitors during off-pump cardiac surgery shows a significant risk of postoperative kidney dysfunction, British researchers say.

The study was prompted by previous research that noted an association between use of aprotinin -- which reduces the risk of bleeding during complicated surgeries -- and renal failure. Drug maker Bayer voluntarily suspended worldwide marketing of aprotinin after preliminary findings from a Canadian study (BART) suggested the drug increased the risk of death. That trial was halted in October 2007. Shortly after that, the U.S. Food and Drug Administration pulled the drug from the American market.

For this study, researchers analyzed the cases of 9,875 cardiac surgery patients. Most of the patients (5,434) had on-pump cardiac surgery, which means their hearts were stopped and they were hooked up to a heart-bypass machine during surgery. The other patients had off-pump cardiac surgery -- doctors operated on their beating hearts.

Among patients who had on-pump surgery, there was no significant association between aprotinin and postoperative renal dysfunction, irrespective of ACE inhibitor use. However, aprotinin was associated with a more than twofold increased risk of renal dysfunction among the 848 patients who had off-pump cardiac surgery and received both aprotinin and ACE inhibitors.

"We recommend that it might be beneficial for patients to discontinue any use of an ACE inhibitor before elective off-pump surgery, particularly patients with a history of renal impairment," wrote Dr. Ronelle Moulton and Kai Zacharowski, from the department of anesthesia, Bristol Royal Infirmary, United Bristol Healthcare Trust.

Their study was published in this week's issue of The Lancet.

A complete analysis of the BART findings will not be known for some time, Dr. Derek Hausenloy, of The Hatter Cardiovascular Institute, University College London Hospital and Medical School, and colleagues wrote in an accompanying comment.

"While waiting for that analysis, the use of aprotinin in the U.S. and in some European countries has been necessarily restricted, with the consequence that some high-risk patients having cardiac surgery might not receive optimum therapy," Hausenloy and colleagues noted.

More information

The U.S. National Heart, Lung, and Blood Institute has more about heart surgery.



-- Robert Preidt



SOURCE: The Lancet, news release, Feb. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Combo Therapy Shows Promise in Treating Brain Tumors
2. Combo Treatment Best for Elderly Lymphoma Patients
3. Combo Therapy Cuts Prostate Cancer Death Rates
4. Drug Combo Halves Death Risk for Severe COPD Patients
5. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
6. New Combo Treatment Extends Kidney Cancer Survival
7. Drug Combo With Antibiotic May Slow MS Progression
8. Combo PET/CT Scan Helps Spot Breast Cancers Spread
9. Drug Combos Effective Against Rheumatoid Arthritis
10. Drug Combo Boosts Multiple Myeloma Survival
11. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
(Date:4/21/2017)... Utah (PRWEB) , ... April 21, 2017 , ... ... wilderness therapy treatment for adolescents and young adults, has kicked off its 4th ... April 23rd. This year’s theme is “Attachment Informed Therapy for Mental Health ...
(Date:4/21/2017)... ... 21, 2017 , ... The Patient Advocacy Community of The Beryl Institute presented ... Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the ... award at The Beryl Institute’s annual Patient Experience Conference on March 20 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... ... Providing for loved ones before one’s passing is of paramount importance. However, ... “Now more than ever there are some questions that are far too critical to ... attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
(Date:4/21/2017)... ... ... During April 21-23, Super-Sod will join the vendor market of the Sacred ... — from the avid gardener to the landscape admirer — during the three-day schedule. ... a grand venue, and we are certainly looking forward to participating in this year’s ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
Breaking Medicine Technology: